Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin
收藏Protein Data Bank Japan2023-10-04 更新2026-03-21 收录
下载链接：
https://pdbj.org/mine/summary/5tq8
下载链接
链接失效反馈官方服务：
资源简介：
Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin Descriptor: Tyrosine-protein kinase JAK2, {2-[6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-2H-indazol-3-yl]-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl}[5-(piperidin-1-yl)pyrazin-2-yl]methanone Authors: Chrencik, J, Jones, P. Deposit date: 2016-10-23 Release date: 2017-01-11 Last modified: 2023-10-04 Method: X-RAY DIFFRACTION (1.59 Å) Cite: Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin. J. Med. Chem., 60, 2017
泛JAK激酶（pan-JAK Kinase）抑制剂临床候选化合物（PF-06263276）的设计与合成：适用于吸入和局部给药，用于治疗肺部与皮肤炎症性疾病
描述靶点：酪氨酸蛋白激酶JAK2（Tyrosine-protein kinase JAK2），化合物结构：{2-[6-(2-乙基-5-氟-4-羟基苯基)-2H-吲唑-3-基]-3,4,6,7-四氢-5H-咪唑并[4,5-c]吡啶-5-基}[5-(1-哌啶基)吡嗪-2-基]甲酮
作者：Chrencik J、Jones P
提交日期：2016-10-23；发布日期：2017-01-11；最后修改日期：2023-10-04
研究方法：X射线衍射（X-RAY DIFFRACTION，分辨率1.59埃）
引用文献：《适用于吸入与局部给药的泛JAK激酶抑制剂临床候选化合物（PF-06263276）的设计与合成：治疗肺部与皮肤炎症性疾病》，《药物化学杂志》（J. Med. Chem.），第60卷，2017年
创建时间：
2016-10-23
